Krystal Biotech reports Q4 EPS $1.52, consensus $1.85

Reports Q4 revenue $91.1M, consensus $91.35M. “Last year, our commercial and financial strength allowed us to deliver significant earnings growth, continue to build out a global footprint, and advance multiple clinical stage programs from our industry-leading HSV-1 based gene delivery platform,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech (KRYS). “Building on this foundation, our focus in 2025 will be on executing the global launch of VYJUVEK and progressing our rare disease and oncology programs through key milestones to bring our redosable genetic medicines closer to patients.”